{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:41Z","timestamp":1792513121653,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Guillain-Barr\u00e9 syndrome (GBS) is considered a rare complication of viral respiratory infections (eg, influenza, severe acute respiratory syndrome coronavirus 2); however, its association with respiratory syncytial virus (RSV) infection has not been studied. We performed a self-controlled case series analysis to estimate GBS risk following medically attended RSV disease among older adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified adults aged \u226565 years with medically attended RSV disease and incident inpatient GBS using specific International Classification of Diseases (ICD) codes, excluding those with prior GBS, from the US Medicare claims data (2011\u20132024). Risk period was 1 to 42 days after the RSV disease index date; the control period encompassed \u2212180 to \u221222 days and 43 to 180 days of RSV disease index date. Conditional Poisson regression estimated RSV-related GBS incidence rate ratios (IRRs), adjusting for seasonality and viral activities. Medicare data policies prohibit cell case counts &amp;lt;11 from being displayed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 452 471 eligible patients with RSV disease, &amp;lt;11 incident GBS cases occurred in the risk period and 34 during the control period. The adjusted IRR for GBS after RSV disease was 2.11 (95% confidence interval, 1.01\u20134.37), consistent across sensitivity analyses of alternative risk\/control periods and after excluding coinfections. The IRR increased to 2.59 (1.17\u20135.73) after ICD-10 code adoption, with a marked rise among patients aged \u226575 years (3.98 [1.45\u201310.91]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>GBS risk increases after RSV disease compared to control periods not temporally adjacent to RSV disease, with an effect particularly evident among patients aged \u226575 years. RSV should be recognized as 1 of the pathogens that may rarely lead to GBS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf621","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:56:49Z","timestamp":1762865809000},"page":"e799-e806","source":"Crossref","is-referenced-by-count":4,"title":["Estimating Risk of Guillain-Barr\u00e9 Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis"],"prefix":"10.1093","volume":"82","author":[{"given":"Caihua","family":"Liang","sequence":"first","affiliation":[{"name":"Vaccines RWE Epidemiology, Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Judy","sequence":"additional","affiliation":[{"name":"Vaccines RWE Epidemiology, Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4417-3398","authenticated-orcid":false,"given":"Erica L","family":"Chilson","sequence":"additional","affiliation":[{"name":"Vaccines RWE Epidemiology, Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P","family":"Kelly","sequence":"additional","affiliation":[{"name":"Vaccines RWE Epidemiology, Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[{"name":"Vaccines RWE Epidemiology, Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D","family":"Maynard","sequence":"additional","affiliation":[{"name":"Strategic Analytics, Value and Economics, ADVI Health , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7015-174X","authenticated-orcid":false,"given":"Heidi","family":"De Souza","sequence":"additional","affiliation":[{"name":"Strategic Analytics, Value and Economics, ADVI Health , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6216-7194","authenticated-orcid":false,"given":"Bradford D","family":"Gessner","sequence":"additional","affiliation":[{"name":"Vaccines RWE Epidemiology, Pfizer Inc. , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-5416","authenticated-orcid":false,"given":"Elizabeth","family":"Begier","sequence":"additional","affiliation":[{"name":"Global Medical Strategy, RSV Adult Vaccine Program, Pfizer Healthcare Ireland , Dublin ,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"2026051309030147900_ciaf621-B1","doi-asserted-by":"crossref","first-page":"e16365","DOI":"10.1111\/ene.16365","article-title":"Guillain-Barre syndrome: a comprehensive review","volume":"31","author":"Bellanti","year":"2024","journal-title":"Eur J Neurol"},{"key":"2026051309030147900_ciaf621-B2","doi-asserted-by":"crossref","first-page":"14222","DOI":"10.3390\/ijms232214222","article-title":"Triggers of Guillain-Barre syndrome: Campylobacter jejuni predominates","volume":"23","author":"Finsterer","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026051309030147900_ciaf621-B3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s12974-021-02319-4","article-title":"Global, regional, and national burden of Guillain-Barre syndrome and its underlying causes from 1990 to 2019","volume":"18","author":"Bragazzi","year":"2021","journal-title":"J Neuroinflammation"},{"key":"2026051309030147900_ciaf621-B4","doi-asserted-by":"publisher","article-title":"Temporal trends and regional variations in mortality related to Guillain-Barre syndrome in the United States: a retrospective study from 1999 to 2020","author":"Nadeem","DOI":"10.1080\/00207454.2024.2401422"},{"key":"2026051309030147900_ciaf621-B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"2026051309030147900_ciaf621-B6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2022.11.003","article-title":"Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019\u20132020","volume":"41","author":"Moll","year":"2023","journal-title":"Vaccine"},{"key":"2026051309030147900_ciaf621-B7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1212\/01.wnl.0000316393.54258.d1","article-title":"Economic cost of Guillain-Barr\u00e9 syndrome in the United States","volume":"71","author":"Frenzen","year":"2008","journal-title":"Neurology"},{"key":"2026051309030147900_ciaf621-B8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10654-019-00596-1","article-title":"Vaccines and the risk of Guillain-Barre syndrome","volume":"35","author":"Chen","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2026051309030147900_ciaf621-B9","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","article-title":"Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection","volume":"27","author":"Patone","year":"2021","journal-title":"Nat Med"},{"key":"2026051309030147900_ciaf621-B10","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1080\/21645515.2021.1985890","article-title":"Risk of Guillain-Barre syndrome following herpes zoster, United States, 2010\u20132018","volume":"17","author":"Anderson","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2026051309030147900_ciaf621-B11","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.3201\/eid1212.051032","article-title":"Influenza, and infections, and hospital admissions for Guillain-Barre syndrome, England","volume":"12","author":"Tam","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"2026051309030147900_ciaf621-B12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1093\/oxfordjournals.aje.a115973","article-title":"Reassessment of the association between Guillain-Barr\u00e9 syndrome and receipt of swine influenza vaccine in 1976\u20131977: results of a two-state study. Expert Neurology Group","volume":"133","author":"Safranek","year":"1991","journal-title":"Am J Epidemiol"},{"key":"2026051309030147900_ciaf621-B13","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1016\/j.vaccine.2022.06.010","article-title":"Safety of COVID-19 vaccination and acute neurological events: a self-controlled case series in England using the OpenSAFELY platform","volume":"40","author":"Walker","year":"2022","journal-title":"Vaccine"},{"key":"2026051309030147900_ciaf621-B14","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1001\/jama.2021.16496","article-title":"Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barr\u00e9 syndrome, February\u2013July 2021","volume":"326","author":"Woo","year":"2021","journal-title":"JAMA"},{"key":"2026051309030147900_ciaf621-B15","doi-asserted-by":"crossref","first-page":"e2094","DOI":"10.1212\/WNL.0000000000207847","article-title":"Risk of Guillain-Barre syndrome following COVID-19 vaccines: a nationwide self-controlled case series study","volume":"101","author":"Le Vu","year":"2023","journal-title":"Neurology"},{"key":"2026051309030147900_ciaf621-B16","doi-asserted-by":"crossref","first-page":"2060668","DOI":"10.1080\/21645515.2022.2060668","article-title":"Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults","volume":"18","author":"Janusz","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"2026051309030147900_ciaf621-B17","doi-asserted-by":"publisher","author":"Lloyd","DOI":"10.1101\/2024.12.27.24319702"},{"key":"2026051309030147900_ciaf621-B18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pediatrneurol.2023.06.013","article-title":"A case of pediatric Guillain-Barre syndrome after respiratory syncytial virus infection","volume":"146","author":"Gupta","year":"2023","journal-title":"Pediatr Neurol"},{"key":"2026051309030147900_ciaf621-B19","doi-asserted-by":"crossref","first-page":"e15733","DOI":"10.1111\/ped.15733","article-title":"A pediatric suspected case of Guillain-Barre syndrome following respiratory syncytial virus RSV infection","volume":"66","author":"Ueshima","year":"2024","journal-title":"Pediatr Int"},{"key":"2026051309030147900_ciaf621-B20","first-page":"21","article-title":"RSV-induced Guillain\u2013Barre syndrome: a case report","volume":"5","author":"Jayakumar","year":"2021","journal-title":"Univ Louisville J Respir Infect"},{"key":"2026051309030147900_ciaf621-B21","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4103\/ijccm.IJCCM_171_17","article-title":"First reported case of respiratory syncytial virus infection causing Guillain-Barre syndrome","volume":"22","author":"Helgeson","year":"2018","journal-title":"Indian J Crit Care Med"},{"key":"2026051309030147900_ciaf621-B22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40121-023-00758-5","article-title":"Low levels of RSV testing among adults hospitalized for lower respiratory tract infection in the United States","volume":"12","author":"Rozenbaum","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026051309030147900_ciaf621-B23","doi-asserted-by":"crossref","first-page":"ofac300","DOI":"10.1093\/ofid\/ofac300","article-title":"Rates of medically attended RSV among US adults: a systematic review and meta-analysis","volume":"9","author":"McLaughlin","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026051309030147900_ciaf621-B24","doi-asserted-by":"crossref","first-page":"ofad513","DOI":"10.1093\/ofid\/ofad513","article-title":"Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries","volume":"10","author":"Njue","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026051309030147900_ciaf621-B25","author":"ResDAC (Research data assistance center)","year":"2025"},{"key":"2026051309030147900_ciaf621-B26","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S1473-3099(10)70140-7","article-title":"Guillain-Barre syndrome after exposure to influenza virus","volume":"10","author":"Lehmann","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"2026051309030147900_ciaf621-B27","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jocn.2020.04.062","article-title":"Guillain Barre syndrome associated with COVID-19 infection: a case report","volume":"76","author":"Sedaghat","year":"2020","journal-title":"J Clin Neurosci"},{"key":"2026051309030147900_ciaf621-B28","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1056\/NEJMc2009191","article-title":"Guillain-Barre syndrome associated with SARS-CoV-2","volume":"382","author":"Toscano","year":"2020","journal-title":"N Engl J Med"},{"key":"2026051309030147900_ciaf621-B29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1017\/cjn.2021.504","article-title":"SARS-CoV-2-associated Guillain-Barre syndrome: a descriptive and comparative analysis","volume":"50","author":"C\u00e1rdenas-Rodr\u00edguez","year":"2023","journal-title":"Can J Neurol Sci"},{"key":"2026051309030147900_ciaf621-B30","doi-asserted-by":"crossref","first-page":"127291","DOI":"10.1016\/j.vaccine.2025.127291","article-title":"Risk of Guillain-Barr\u00e9 syndrome after COVID-19 vaccination or SARS-CoV-2 infection: a multinational self-controlled case series study","volume":"60","author":"Nasreen","year":"2025","journal-title":"Vaccine"},{"key":"2026051309030147900_ciaf621-B31","doi-asserted-by":"crossref","first-page":"100578","DOI":"10.1016\/j.bbih.2022.100578","article-title":"Guillain-Barre syndrome associated with COVID-19: a systematic review","volume":"28","author":"Pimentel","year":"2023","journal-title":"Brain Behav Immun Health"},{"key":"2026051309030147900_ciaf621-B32","doi-asserted-by":"crossref","first-page":"e16094","DOI":"10.1111\/ene.16094","article-title":"Guillain-Barre syndrome and SARS-CoV-2 infection: a systematic review and meta-analysis on a debated issue and evidence for the \u2018Italian factor\u2019","volume":"31","author":"Censi","year":"2024","journal-title":"Eur J Neurol"},{"key":"2026051309030147900_ciaf621-B33","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/aje\/kwn310","article-title":"Investigation of the temporal association of Guillain-Barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database","volume":"169","author":"Stowe","year":"2009","journal-title":"Am J Epidemiol"},{"key":"2026051309030147900_ciaf621-B34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10654-015-0047-0","article-title":"Risk of Guillain-Barr, syndrome after exposure to pandemic influenza A(H1N1)pdm09 vaccination or infection: a Norwegian population-based cohort study","volume":"31","author":"Ghaderi","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"2026051309030147900_ciaf621-B35","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s40121-024-00974-7","article-title":"Respiratory syncytial virus sequelae among adults in high-income countries: a systematic literature review and meta-analysis","volume":"13","author":"Ubamadu","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026051309030147900_ciaf621-B36","author":"UK health security agency","year":"2025"},{"key":"2026051309030147900_ciaf621-B37","doi-asserted-by":"crossref","first-page":"696","DOI":"10.15585\/mmwr.mm7332e1","article-title":"Use of respiratory syncytial virus vaccines in adults aged \u226560 years: updated recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2024","volume":"73","author":"Britton","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026051309030147900_ciaf621-B38","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(24)01738-0","article-title":"Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis","volume":"404","author":"Payne","year":"2024","journal-title":"Lancet"},{"key":"2026051309030147900_ciaf621-B39","doi-asserted-by":"publisher","author":"Symes","DOI":"10.1016\/S1473-3099(25)00546-8"},{"key":"2026051309030147900_ciaf621-B40","author":"USFDA","year":"2025"},{"key":"2026051309030147900_ciaf621-B41","doi-asserted-by":"crossref","first-page":"e258322","DOI":"10.1001\/jamanetworkopen.2025.8322","article-title":"Effectiveness and safety of respiratory syncytial virus vaccine for US adults aged 60 years or older","volume":"8","author":"Fry","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026051309030147900_ciaf621-B42","doi-asserted-by":"crossref","first-page":"24561","DOI":"10.1038\/s41598-024-74729-2","article-title":"Global burden of vaccine-associated Guillain-Barr\u00e9 syndrome over 170 countries from 1967 to 2023","volume":"14","author":"Jeong","year":"2024","journal-title":"Sci Rep"},{"key":"2026051309030147900_ciaf621-B43","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3201\/eid2102.131879","article-title":"Simulation study of the effect of influenza and influenza vaccination on risk of acquiring Guillain-Barre syndrome","volume":"21","author":"Hawken","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2026051309030147900_ciaf621-B44","doi-asserted-by":"crossref","first-page":"03037","DOI":"10.7189\/jogh.14.03037","article-title":"Selecting the most informative positive and negative controls for self-controlled case series (SCCS): rationale, approach, and lessons from studies investigating the safety of COVID-19 vaccines","volume":"14","author":"Rudan","year":"2024","journal-title":"J Glob Health"},{"key":"2026051309030147900_ciaf621-B45","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/irv.12665","article-title":"Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance","volume":"14","author":"Cai","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"2026051309030147900_ciaf621-B46","doi-asserted-by":"crossref","first-page":"e0319436","DOI":"10.1371\/journal.pone.0319436","article-title":"Evaluating the accuracy of ICD-10 codes for syncytial respiratory virus diagnosis in hospitalized patients: a record-linkage study (2022\u20132023)","volume":"20","author":"Bierrenbach","year":"2025","journal-title":"PLoS One"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf621\/65288056\/ciaf621.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e799\/65288056\/ciaf621.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/4\/e799\/65288056\/ciaf621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T13:03:15Z","timestamp":1778677395000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/4\/e799\/8322890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,11,14]]},"published-print":{"date-parts":[[2026,4,30]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf621","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,11,14]]}}}